Lifecore Biomedical Inc (LFCR) valuation
Lifecore Biomedical P/E ratio history
Lifecore Biomedical has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 3 fiscal year ends its P/E ranged from 15.8 (year to May 2018) to 35.0 (year to May 2017), with a median of 17.0.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| May 25, 2025 | $6.72 | -$1.26 | n/m |
| May 26, 2024 | $5.62 | $0.33 | 17.0 |
| May 28, 2023 | $7.94 | -$3.32 | n/m |
| May 29, 2022 | $9.87 | -$3.97 | n/m |
| May 30, 2021 | $11.97 | -$1.10 | n/m |
| May 31, 2020 | $10.67 | -$1.31 | n/m |
| May 26, 2019 | $9.42 | $0.01 | n/m |
| May 27, 2018 | $14.05 | $0.89 | 15.8 |
| May 28, 2017 | $13.65 | $0.39 | 35.0 |
| May 29, 2016 | $11.46 | -$0.43 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Lifecore Biomedical valuation against its peers
| Company | Market value | P/E | Price / sales |
|---|---|---|---|
| Lifecore BiomedicalLFCR | $240M | — | — |
| EvommuneEVMN | $242M | 1.2 | 24.2 |
| Fate TherapeuticsFATE | $242M | — | 37.3 |
| Standard BiotoolsLAB | $238M | 2.8 | 2.8 |
| AlectorALEC | $245M | — | 17.7 |
| Fulcrum TherapeuticsFULC | $247M | — | — |
| Lexeo TherapeuticsLXEO | $247M | — | — |
| Abeona TherapeuticsABEO | $248M | — | 9.7 |
| Vanda PharmaceuticalsVNDA | $228M | — | 1.1 |
| Peer median | 2.0 | 13.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: LFCR financials · LFCR returns
No forecast, no recommendation. This page describes Lifecore Biomedical Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.